Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

New investor Aperture joins in for Yaupon’s $14.4mm Series D round

Executive Summary

Rare cancer drug developer Yaupon Therapeutics Inc. has raised $14.4mm in Series D financing from first-time backer Aperture Venture and existing investors Vivo Ventures, Palo Alto Investors, and Burrill & Co. The money will support the company’s lead candidate, topical mechlorethamine gel, as the FDA reviews the NDA (which was filed just weeks ago) for stage I-IIa mycosis fungoides, the most common form of cutaneous T-cell lymphoma.
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies